Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS study

CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies

“…Dose reductions were reported in 11 studies (Supplementary Appendix 2) [41,43,45,[47][48][49]51,61,[65][66][67]. The proportion of patients with dose reductions for palbociclib plus AI ranged from 17.4 [57] to 31.3% [61] during first-line therapy, while a broader range of 10.8 [67] to 72.1% (the highest reported incidence of this outcome) [45] was observed across all lines of therapy (Table 3). For palbociclib plus fulvestrant, dose reduction rates were 34.3% during first-line therapy [66], 33.3% during second-and subsequent-lines of therapy [47], and ranged from 11.1 [67] to 64.6% [45] across all lines of therapy.…”

“…Treatment discontinuations for any reason (e.g., side effects, patient decision and completion of planned treatment) were reported in ten studies (Supplementary Appendix 2) [41,43,45,[47][48][49]51,61,64,67]. For palbociclib plus AI, discontinuation rates ranged from 22.9 [61] to 45.6% [57] during first-line therapy, and more broadly from 15.5 [67] to 79.4% (the highest reported incidence of treatment discontinuations) [41] across all lines of therapy (Table 3). For palbociclib plus fulvestrant, discontinuation rates ranged from 12.7 (the lowest reported incidence of treatment discontinuations) [67] to 19.9% [45] across all lines of therapy, and was higher (60%) in second-or subsequent-line treatment [47].…”

“…For palbociclib plus AI, discontinuation rates ranged from 22.9 [61] to 45.6% [57] during first-line therapy, and more broadly from 15.5 [67] to 79.4% (the highest reported incidence of treatment discontinuations) [41] across all lines of therapy (Table 3). For palbociclib plus fulvestrant, discontinuation rates ranged from 12.7 (the lowest reported incidence of treatment discontinuations) [67] to 19.9% [45] across all lines of therapy, and was higher (60%) in second-or subsequent-line treatment [47]. For ribociclib plus AI, 38.7% discontinued first-line treatment [49].…”

“…Treatment discontinuations due to disease progression as a proportion of the total number of discontinuations during study follow-up time were reported in seven studies [41,45,49,51,61,64,67]. Of note, two of these studies reported rates of primary progression (i.e., disease progression with no response to treatment), which ranged from 6.7 [67] to 35.7% [41] of patients receiving palbociclib plus AI in all lines, and was 12.5% of patients receiving palbociclib plus fulvestrant in all lines [67].…”

“…Treatment discontinuations due to disease progression as a proportion of the total number of discontinuations during study follow-up time were reported in seven studies [41,45,49,51,61,64,67]. Of note, two of these studies reported rates of primary progression (i.e., disease progression with no response to treatment), which ranged from 6.7 [67] to 35.7% [41] of patients receiving palbociclib plus AI in all lines, and was 12.5% of patients receiving palbociclib plus fulvestrant in all lines [67]. For palbociclib plus AI, progression-related discontinuation rates ranged from 50 [61] to 95.5% of total discontinuations (the highest reported incidence of this outcome) [51] during first-line therapy, and from 16.7 [67] (the lowest reported incidence of this outcome) to 84% [41] in all lines (Table 3).…”